#USA #Fremont #Alamar Biosciences #NULISAseq #DZNE

Alamar Biosciences Collaborates with DZNE for Proteomic Profiling

Alamar Biosciences has announced an exciting partnership with the German Center for Neurodegenerative Diseases (DZNE) to launch a significant proteomic profiling study as part of the Rhineland Study cohort. This initiative seeks to utilize Alamar’s revolutionary NULISAseq technology, which aims to empower early disease detection through precision proteomics.

The Rhineland Study is one of the most extensive longitudinal aging studies globally and is designed to explore the determinants of healthy aging and neurodegenerative diseases. With plans to analyze 23,000 plasma samples, this collaboration is set to enhance our understanding of aging and its associated challenges.

Advancements in Biomarker Discovery

Prof. Monique Breteler, Director of Population Health Sciences at DZNE, highlighted the importance of advanced technology in understanding aging and dementia. “Integrating Alamar's multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging,” she expressed. This partnership allows researchers to measure numerous brain-related proteins efficiently using minimal blood samples while ensuring exceptional sensitivity and specificity.

One of the standout features of the CNS Disease Panel 120 is its ability to differentiate between brain-derived phosphorylated tau and total phosphorylated tau in plasma. This advancement is crucial for early detection and risk stratification of neurodegenerative conditions, particularly Alzheimer’s disease. Additionally, the NULISAseq Inflammation Panel 250 will provide the most comprehensive profiling of immune-related proteins, highlighting their roles in aging and neuroinflammation linked to neurodegenerative diseases.

Combining Proteomic Data with Holistic Datasets

The comprehensive proteomic data resulting from this analysis will be integrated with extensive clinical, demographic, and imaging datasets collected from the study. This integration is pivotal for identifying early biomarkers and enhancing the development of precision diagnostics and targeted therapies. Dr. Yuling Luo, Founder and CEO of Alamar Biosciences, noted, “This partnership marks a major step forward in aging and dementia research. With the unmatched sensitivity of NULISA and the depth of the DZNE Rhineland Study, we can identify novel protein biomarkers that shed light on cognitive health trajectories and disease progression in older populations.”

Commitment to Research Excellence

Both organizations showcase a deep commitment to scientific rigor, inclusivity, and innovation in the realm of neurodegenerative disease research. By documenting diverse aging trajectories in a thoroughly characterized population, Alamar Biosciences and DZNE are set to pave the way for improved diagnosis, prognosis, and new therapeutic avenues for age-related brain disorders.

Insights into the DZNE Rhineland Study

The DZNE Rhineland Study represents a monumental effort to analyze various determinants of healthy aging and neurodegeneration through a longitudinal cohort of thousands of individuals. By harmonizing clinical, imaging, genetic, and lifestyle data, researchers can gain profound insights into the complexities of the aging brain. For more information about their ongoing initiatives, visit their website at www.dzne.de/en/ and details about the Rhineland Study at www.rheinland-studie.de/en/.

About Alamar Biosciences

Founded with the mission of enabling the earliest disease detection through precision proteomics, Alamar Biosciences is at the forefront of biotechnological innovation. Their proprietary NULISA Platform, combined with the ARGO HT System, delivers exceptional detection sensitivity, aiding in the identification of critical health indicators long before clinical symptoms arise. To learn more about Alamar Biosciences, visit www.alamarbio.com.